Analysts’ Opinions Are Mixed on These Healthcare Stocks: T2 Biosystems (TTOO) and Chimerix (CMRX)


Analysts have been eager to weigh in on the Healthcare sector with new ratings on T2 Biosystems (TTOO) and Chimerix (CMRX).

T2 Biosystems (TTOO)

Canaccord Genuity analyst Mark Massaro maintained a Buy rating on T2 Biosystems today and set a price target of $10. The company’s shares opened today at $4.29.

Massaro wrote:

“We’d like to provide our view and counter the key points made in the report: Point 1 – News of T2’s recent “Breakthrough Device designation by the FDA isn’t an acknowledgement of the device’s effectiveness or clinical value proposition, or that the device has value, only that it diagnoses life-threatening disease. Our response – This is true, but it’s still a positive. T2 just started its dialogue with the FDA on its T2Resistance panel, thus FDA has not reviewed data from T2. We believe that breakthrough device designation will (1) add more resources by the FDA on this device and (2) likely provide a speedier review process and ultimately FDA approval.”

According to TipRanks.com, Massaro is a 5-star analyst with an average return of 17.5% and a 59.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as Meridian Bioscience Inc, Quanterix Corporation, and Orasure Technologies.

Currently, the analyst consensus on T2 Biosystems is a Strong Buy with an average price target of $11.67, a 172.0% upside from current levels. In a report issued on February 27, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $11 price target.

See today’s analyst top recommended stocks >>

Chimerix (CMRX)

Cowen & Co. analyst Phil Nadeau maintained a Hold rating on Chimerix today and set a price target of $2. The company’s shares opened today at $2.24, close to its 52-week low of $1.88.

According to TipRanks.com, Nadeau is a 5-star analyst with an average return of 8.9% and a 52.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Voyager Therapeutics Inc, and Alexion Pharmaceuticals.

Chimerix has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts